多重用药及潜在不适当用药与老年癌症患者不良结局的系统综述与荟萃分析
该系统综述与荟萃分析纳入42篇观察性研究,评估≥60岁癌症患者中多重用药或潜在不适当用药(PIM)与五种预设不良结局的关联。多重用药与全因死亡、住院、治疗相关毒性及术后并发症显著相关,PIM仅与全因死亡显著相关。约四分之三研究未校正合并症,结果需谨慎解读。
要点
- 多重用药与老年癌症患者全因死亡、住院、治疗毒性及术后并发症显著相关。
- PIM仅与全因死亡显著相关,与其他不良结局无显著关联。
- 多数研究未校正合并症,存在适应证混杂,结论需谨慎解读。
核心结论
- 多重用药与老年癌症患者多种不良结局相关,PIM使用与全因死亡相关。
- 结果需谨慎解读,因约四分之三研究未校正合并症且易发生适应证混杂。
研究设计与样本
- 系统综述与荟萃分析,纳入前瞻性或回顾性观察性研究,报告多重用药或PIM与至少一种预设不良结局的关联。
- 研究对象为≥60岁老年癌症患者,检索PubMed和Web of Science 1991年1月至2020年3月发表的文献。
- 共纳入42篇文献,其中39项研究可进行多重用药荟萃分析,13项可进行PIM荟萃分析,采用随机效应模型合并数据。
主要发现
- 多重用药与全因死亡风险比1.37(95%CI 1.25-1.50)显著相关。
- 多重用药与住院风险比1.53(95%CI 1.37-1.71)显著相关。
- 多重用药与治疗相关毒性风险比1.22(95%CI 1.01-1.47)显著相关。
- 多重用药与术后并发症风险比1.73(95%CI 1.36-2.20)显著相关。
关键数值与推荐
- 多重用药与全因死亡、住院、治疗相关毒性、术后并发症的关联均具统计学显著性。
- PIM仅与全因死亡的关联具统计学显著性。
临床怎么用
- 对老年癌症患者应关注多重用药,其与死亡、住院、治疗毒性及术后并发症风险升高相关。
- 评估PIM使用有助于识别全因死亡风险较高的老年癌症患者。
- 解读关联时需考虑合并症未校正及适应证混杂的可能影响。
局限性
- 约四分之三的研究未校正合并症,结果易受混杂影响。
- 研究易发生适应证混杂。
- 结果应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both polypharmacy and potentially inappropriate medication (PIM) intake are highly prevailing in older cancer patients. However, only studies on the association of polypharmacy and postoperative complications have been meta-analyzed previously. METHODS: A systematic review and a meta-analysis of prospective/retrospective observational studies reporting associations of polypharmacy or PIM with at least one out of five predefined adverse health outcomes in a population of older cancer patients (≥60 years) were carried out. PubMed and Web of Science were used to search for relevant studies published between January 1991 and March 2020. Data were pooled by adopting a random-effects model. RESULTS: Overall, 42 publications were included in the systematic review. Meta-analyses could be performed on 39 studies about polypharmacy and 13 studies about PIM. Polypharmacy was found to be statistically significantly associated with all-cause mortality (risk ratio [95% confidence interval]: 1.37 [1.25-1.50]), hospitalization (1.53 [1.37-1.71]), treatment-related toxicity (1.22 [1.01-1.47]), and postoperative complications (1.73 [1.36-2.20]). The association of polypharmacy with prolongation of hospitalization was not statistically significant at the p < .05 significance level (1.62 [0.98-2.66]). With respect to PIM, a statistically significant association with all-cause mortality (1.43 [1.08-1.88]) was observed but not with other adverse outcomes. CONCLUSIONS: Polypharmacy was found to be associated with several adverse outcomes and PIM use with all-cause mortality in older cancer patients. However, these results should be interpreted with caution because about three-quarters of the studies identified did not adjust for comorbidity and are prone to confounding by indication.
引用
- Chen LJ, Trares K, Laetsch DC, et al. Systematic Review and Meta-Analysis on the Associations of Polypharmacy and Potentially Inappropriate Medication With Adverse Outcomes in Older Cancer Patients. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32459845. doi:10.1093/gerona/glaa128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。